// App-Quantinova.ai

417 : Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.

Researchers

Presenter

  • Andrea Wang-Gillam

Principal Investigators

  • Gyorgy Bodoky

  • Andrew Dean

  • Yang-Shen Shan

  • Gayle S. Jameson

  • Teresa Macarulla

  • Kyung-Hun Lee

  • David Cunningham

  • Jean-Frdric Blanc

  • Richard Hubner

  • Chang-Fang Chiu

  • Gilberto Schwartsmann

  • Jens T Siveke

  • Fadi S. Braiteh

  • Victor M. Moyo

  • Bruce Belanger

  • Eliel Bayever

  • Daniel D. Von Hoff

  • Li-Tzong Chen

Medical Centers

  • Washington University in St Louis, St. Louis, MO

  • St. Laszlo Teaching Hospital, Budapest, Hungary

  • St. John of God Hospital, Subiaco, Australia

  • National Institute of Cancer Research, National Health Institutes and National Cheng Kung University Hospital, Tainan, Taiwan

  • TGen, Banner Health, Phoenix, Scottsdale, AZ

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Royal Marsden Hospital, Surrey, United Kingdom

  • Hopital Saint-Andre, Bordeaux, France

  • Christie Hospital NHS Foundation Trust, Altrincham, United Kingdom

  • China Medical University Hospital, Taichung, Taiwan

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • Klinikum rechts der Isar der TU Muenchen, Munich, Germany

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Merrimack Pharmaceuticals, Cambridge, MA

  • National Health Research Institutes (NHRI) - National Institute of Cancer Research, Taipei, Taiwan

Locations

  • United States

  • Taiwan

  • Hungary

  • Australia

  • Spain

  • Republic of South Korea

  • United Kingdom

  • France

  • Brazil

  • Germany

Companies

  • Merrimack Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • 5-fluorouracil + leucovorin

  • Irinotecan

  • Adrucil injection

  • Fluorouracil

  • Gemcitabine

  • leucovorin

  • Irinotecan sucrosofate

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01494506

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved